The European Commission (EC) has approved marketing authorisation for Switzerland-based Roche's Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy for initial treatment of people with a specific type of metastatic lung cancer, it was reported yesterday.
The EC has approved the product in combination with Avastin, paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer. The Tecentriq combination is only indicated after failure of appropriate targeted therapies in patients with EGFR mutant or ALK-positive non-small cell lung cancer.
The approval was based on data from the phase III IMpower150 study, which indicated that Tecentriq in combination with Avastin and chemotherapy enabled people to live longer compared against Avastin and chemotherapy. IMpower150 is a multicentre, open-label, randomised and controlled phase III study designed to evaluate the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel) with or without Avastin in people with stage IV or recurrent metastatic non-squamous non-small cell lung cancer who had not been treated with chemotherapy for their advanced disease. The company hired 1,202 patients in the trial, and randomised to secure Tecentriq plus carboplatin and paclitaxel in the arm A, Tecentriq and Avastin plus carboplatin and paclitaxel in the arm B and Avastin plus carboplatin and paclitaxel Arm C or control arm.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886